BTIG Reiterates Buy Rating on Kazia Therapeutics, Sets $34 Target
BTIG reaffirms its buy rating on Kazia Therapeutics, maintaining a price target of $34, a 141.48% upside from the current price.
Key Points
- BTIG analyst Kambiz Yazdi reiterated a buy rating on Kazia Therapeutics, setting a price target of $34.
- BTIG's $34 price target implies 141.48% upside from Kazia Therapeutics Limited's ($KZIA) current $14.08 share price.
- Kazia Therapeutics shares traded at $14.08 on Wednesday, with a market cap of approximately $160.9 million.
- Insiders at Kazia Therapeutics recently bought shares, and other analysts have set targets ranging from $18 to $32.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BTIG has reiterated its buy rating on Kazia Therapeutics Limited (NasdaqCM:KZIA), setting a price target of $34. This reaffirmation by analyst Kambiz Yazdi was made on July 1, 2026. Shares of Kazia traded at $14.08 on Wednesday.
BTIG vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Kazia Therapeutics Limited Stock Up 3.7%
Shares of NasdaqCM:KZIA traded near $14.08 on Wednesday. Kazia Therapeutics has a market cap of about $160.9 million and a beta of 2.181, indicating it is more volatile than the overall market. The stock's 52-week range has been between $4.86 and $17.4, with a 50-day moving average of $12.87 and a 200-day moving average of $9.10.
$KZIA price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Kazia Therapeutics Limited
Recent insider activity at Kazia Therapeutics saw Chief Scientific Officer Sudha Rao and Chief Financial Officer James Levine each purchasing 250,000 and 200,000 shares, respectively, on June 19, 2026. These transactions were not part of a pre-arranged trading plan.
Analysts Set New Price Targets
On July 1, 2026, BTIG reiterated its buy rating on Kazia Therapeutics with a price target of $34. Previously, Lake Street initiated coverage with a buy rating and a $32 target on June 11, 2026. Laidlaw & Co. also initiated coverage with a buy rating and a $25 target on April 15, 2026. The consensus among analysts is a buy rating, with an average target price of approximately $25.44 based on four analyst opinions.
About Kazia Therapeutics
Kazia Therapeutics Limited is a biotechnology company based in Sydney, Australia. It focuses on developing cancer treatments, with its lead product, paxalisib, targeting various brain cancers. The company is also working on EVT801, aimed at treating advanced solid tumors. Kazia collaborates with several research groups and companies to further its drug development efforts. The company operates with a small team of six employees and is led by CEO Dr. John Edwin Friend II.
Bottom Line
BTIG's reaffirmation of a buy rating for Kazia Therapeutics, along with a $34 target, highlights continued interest in the company's potential. Investors should note that analyst ratings are based on projections and should consider the company's financials and market conditions. Kazia's insider buying activity and collaborations in the biotechnology sector are points of interest for stakeholders.
Get Kazia Therapeutics Limited alerts
New 13F filings, insider trades, and analyst moves on $KZIA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.